+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
UCB (Union chimique belge) - logo

UCB is a global biopharmaceutical company that focuses on neurology and immunology. The company’s core products are Cimzia, Vimpat, Neupro, Keppra and Briviact, and they are also preparing the launch of a potential medicine to help patients with osteoporosis. It offers products for the treatment of central nervous system disorders, allergy and respiratory diseases, and immune and inflammatory disorders. UCB employs over 7,000 people and is based in Brussels, Belgium.

Anticonvulsants Global Market Report 2024 - Product Thumbnail Image

Anticonvulsants Global Market Report 2024

  • Report
  • January 2024
  • 200 Pages
  • Global
From
Neurodegenerative Disorder Therapeutics Global Market Report 2024 - Product Thumbnail Image

Neurodegenerative Disorder Therapeutics Global Market Report 2024

  • Report
  • February 2024
  • 250 Pages
  • Global
From
Anti-Parkinson Drugs Global Market Report 2024 - Product Thumbnail Image

Anti-Parkinson Drugs Global Market Report 2024

  • Report
  • November 2023
  • 175 Pages
  • Global
From
From
Myasthenia Gravis Disease - Global Clinical Trials Review, H1, 2021 - Product Thumbnail Image

Myasthenia Gravis Disease - Global Clinical Trials Review, H1, 2021

  • Clinical Trials
  • February 2021
  • 138 Pages
  • Global
From
Epilepsy Disease - Global Clinical Trials Review, H1, 2021 - Product Thumbnail Image

Epilepsy Disease - Global Clinical Trials Review, H1, 2021

  • Clinical Trials
  • February 2021
  • 1436 Pages
  • Global
From
Epilepsy - Pipeline Insight, 2024 - Product Thumbnail Image

Epilepsy - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 240 Pages
  • Global
From
Partial Epilepsy - Pipeline Insight, 2024 - Product Thumbnail Image

Partial Epilepsy - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Myasthenia Gravis - Pipeline Insight, 2024 - Product Thumbnail Image

Myasthenia Gravis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Partial Seizure - Pipeline Insight, 2024 - Product Thumbnail Image

Partial Seizure - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
From
Parkinson's disease - Pipeline Insight, 2024 - Product Thumbnail Image

Parkinson's disease - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 230 Pages
  • Global
From
Refractory Epilepsy - Pipeline Insight, 2024 - Product Thumbnail Image

Refractory Epilepsy - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
From
From
Loading Indicator